Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company p...
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $...
https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07162025_ENSC_Sorensen.pdf
~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~SAN DIEGO, CA / ACCESS Newswire / July 16, ...
~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Developmen...
